Senicapoc
Senicapoc is a pharmaceutical drug with 7 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
3
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
Senicapoc and Perampanel for Newly Diagnosed Glioblastoma
Senicapoc in Alzheimer's Disease
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
Clinical Trials (7)
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
Senicapoc and Perampanel for Newly Diagnosed Glioblastoma
Senicapoc in Alzheimer's Disease
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma
Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7